Alectinib is a Small Molecule owned by Chugai Pharmaceutical, and is involved in 67 clinical trials, of which 28 were completed, and 39 are ongoing.

Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor. It blocks the signal from echinoderm microtubule-associated protein-like 4 (EML4) to ALK. This blockage is done by inhibiting the activity of ALK. The chromosomal rearrangements (translocations) that interrupt the ALK gene and fuse it with another gene result in the creation of oncogenic ALK fusion genes that enhance cell proliferation and survival. When blocked, it is possible to stop growth and division of the cancer cells stopping the cancer cells to increase.

The revenue for Alectinib is expected to reach a total of $31.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Alectinib NPV Report.

Alectinib is originated and owned by Chugai Pharmaceutical. F. Hoffmann-La Roche is the other company associated in development or marketing of Alectinib.

Alectinib Overview

Alectinib (Alecensa/Alecensaro) is an antineoplastic agent. It is an anaplastic lymphoma kinase (ALK) inhibitor. It is formulated as hard gelatin capsules for oral route of administration. Alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib and as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). Alecensa is also indicated for recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma.

Alectinib is under development for the treatment of central nervous system (CNS) tumor, advanced or metastatic solid tumors, non-small cell lung cancer (NSCLC) as an adjuvant therapy and first line therapy. It is administered through oral route as a capsule.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Alectinib

Report Segments
  • Innovator (NME)
Drug Name
  • Alectinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.